How to Value a Cosmetic Dermatology Practice in 2026

Cosmetic-only dermatology — pure aesthetics with no medical derm, no insurance billing, no Mohs surgery — is one of the most misunderstood practice types in healthcare M&A. Buyers either overpay because they see glamorous margins or underpay because they don't understand the unit economics. Neither approach serves the seller well.

I've worked on cosmetic derm transactions ranging from solo injectors doing $600K in revenue to multi-provider med spas doing $5M+. The valuation dynamics shift dramatically across that spectrum, and the metrics that matter are different from anything you'd see in medical dermatology or general healthcare.

The Valuation Framework: 4-8x SDE

Cosmetic-only dermatology practices typically trade at 4-8x SDE. The reason buyers use SDE rather than EBITDA for most cosmetic practices is straightforward: the owner is almost always a producing provider, and their personal production is inseparable from the revenue. Until you have 3+ injectors and the owner is purely managing, SDE is the right metric.

At 4x SDE, you're looking at a solo-provider practice where the owner does 80%+ of treatments, has limited brand recognition beyond personal reputation, and relies on word-of-mouth rather than systematic marketing. At 8x, it's a branded practice with multiple providers, strong digital presence, 60%+ patient retention year-over-year, and margins that demonstrate the model works without the founder in the treatment room.

For larger practices ($2M+ revenue, 4+ providers), buyers shift to EBITDA-based valuation at 6-10x, especially when private equity is involved. The PE interest in cosmetic dermatology has accelerated since 2023, with firms seeing the recurring nature of injectables and the demographic tailwinds of an aging but appearance-conscious population.

The Cash-Pay Advantage (and Its Hidden Risks)

The defining characteristic of cosmetic derm is that it's entirely cash-pay. No insurance contracts, no claim denials, no prior authorizations, no accounts receivable aging over 90 days. Revenue is collected at the time of service. For buyers who've dealt with the misery of insurance-dependent practices, this is enormously attractive.

Cash-pay also means higher margins. A well-run cosmetic practice operates at 40-55% SDE margins versus 25-35% for insurance-dependent medical practices. The absence of billing staff, coding specialists, and collection infrastructure removes a significant overhead category.

But cash-pay carries risks that buyers must understand. The revenue is entirely discretionary — patients choose to spend on Botox and fillers the same way they choose to spend on vacations and handbags. In economic downturns, cosmetic spending contracts faster than medical spending. I saw this clearly during 2020 and again during the 2022-2023 rate hike cycle: practices that had grown 15-20% annually suddenly went flat or declined. Buyers who lived through that adjust their multiples accordingly.

The implication for sellers: if you're going to market during a period of strong consumer spending, time works in your favor. Your trailing twelve months will look great. If the economy softens, expect buyers to apply a discount for economic sensitivity that can compress your multiple by 1-2x.

Injector Revenue Per Hour: The Core Unit Economic

In cosmetic dermatology, the metric that matters most is revenue per injector hour. This captures the intersection of pricing power, efficiency, patient mix, and provider skill in a single number. The range is wide: $500-1,500 per hour, and where you fall determines your valuation.

At $500/hour, you're doing primarily basic neurotoxin injections (Botox, Dysport) at competitive pricing, treating one patient every 30-45 minutes. The margins are acceptable but not exceptional, and you're competing on price with every med spa and dentist offering injectables.

At $1,000-1,500/hour, you're combining neurotoxins with dermal fillers, PDO threads, PRP, and device-based treatments (lasers, RF microneedling) in combination protocols that average $2,000-4,000 per patient visit. You're treating patients who value expertise over price, and your provider is skilled enough to deliver complex, multi-modality treatments efficiently.

Buyers analyze this metric closely because it predicts scalability. A practice generating $1,200/hour per injector can add a second or third provider and maintain that productivity. A practice generating $500/hour is already at the commodity end of the market and adding providers doesn't scale — it just adds headcount competing for the same price-sensitive patients.

Patient Retention: The Recurring Revenue of Aesthetics

Cosmetic derm has something most cash-pay businesses don't: naturally recurring demand. Botox lasts 3-4 months. Fillers last 6-18 months. Skin tightening treatments need annual maintenance. A patient who starts with neurotoxins at age 35 may be a customer for 30+ years.

The metric buyers focus on is annual patient retention rate — the percentage of active patients from the prior year who return for at least one treatment in the current year. The range I see:

• Below 50%: Red flag. Patients are coming once and not returning, which signals quality issues, pricing problems, or poor patient experience.
• 50-60%: Average. Typical for practices relying on discounting and deal platforms to drive volume.
• 60-75%: Strong. Indicates good patient experience, appropriate pricing, and effective rebooking systems.
• 75%+: Exceptional. Usually seen in practices with membership programs, loyalty rewards, and strong provider-patient relationships.

Practices with 70%+ retention are effectively generating recurring revenue in a cash-pay model. That's extraordinarily attractive to buyers and justifies multiples at the top of the range. Build a membership or loyalty program that locks in quarterly treatment cadences, and you've created something that looks almost like a subscription business.

Marketing ROI: The Cost of Growth

Cosmetic dermatology is one of the most marketing-intensive healthcare businesses. Unlike medical practices where patients are referred by other providers, cosmetic patients find you through Instagram, Google Ads, TikTok, and Yelp. Marketing spend of 10-18% of revenue is standard, and buyers scrutinize the efficiency of that spend carefully.

The metrics that matter:

Cost per new patient acquisition. The range is $150-500 depending on market competitiveness. A practice in Manhattan might spend $400 per new patient; one in suburban Raleigh might spend $175. Neither is inherently better — what matters is whether the lifetime value of that patient justifies the acquisition cost. At a 65% retention rate and $3,000 annual spend per patient, the lifetime value is roughly $15,000-20,000. Against that, even a $400 acquisition cost is excellent.

Channel concentration. If 70%+ of your new patients come from a single channel (say, Instagram), you have a vulnerability. Algorithm changes, ad cost increases, or platform policy shifts could crater your patient acquisition overnight. Buyers prefer diversified marketing across paid social, organic search, referrals, and events.

Brand versus performance marketing.Practices that have built genuine brand equity — recognized name, strong Google reviews (4.8+ stars with 200+ reviews), active social following — have a marketing moat that reduces future customer acquisition costs. Practices dependent entirely on paid advertising have no moat, and their marketing spend is effectively a recurring cost that can't be reduced without losing volume.

What Destroys Cosmetic Practice Value

Provider-dependent revenue. If the owner-injector generates 70%+ of revenue and patients book specifically with them, the practice has a severe owner dependency problem. Buyers know that 20-40% of patients may leave when the signature provider departs. Building a team where multiple injectors have their own patient followings is the most effective way to address this.

Discounting addiction. Practices that rely on Groupon, heavy promotions, and aggressive discounting to drive volume train patients to only buy on sale. These patients have near-zero loyalty and will follow the next coupon to a competitor. Buyers view promotional revenue as low-quality and will discount it 30-50% in their valuation model.

Regulatory exposure. Cosmetic practices that use non-physician injectors (NPs, PAs, RNs) must comply with state-specific supervision requirements. A practice operating outside those requirements — even if common in the market — carries regulatory risk that institutional buyers cannot tolerate. Ensure your medical director oversight structure is airtight and documented.

Product concentration. A practice where 80% of revenue comes from a single product line (e.g., only neurotoxins) is vulnerable to pricing pressure and competitive entry. Diversification across injectables, devices, skin care products, and body contouring demonstrates a fuller service offering that retains patients across multiple needs.

Preparing for a Premium Exit

The cosmetic practices that sell at 7-8x SDE (or transition to EBITDA-based valuations at even higher multiples) share common characteristics. Here's how to build toward that outcome:

Hire and develop additional injectors. Get at least one other provider to 30-40% of total revenue. Give them their own patient following, their own social media presence, and their own treatment specialties. This is the single highest-ROI action for reducing owner dependency.

Launch a membership program. Monthly or quarterly memberships that include neurotoxin treatments, skin care products, and treatment discounts create predictable revenue and dramatically improve retention. Practices with 200+ active members are essentially proving recurring revenue in a cash-pay model.

Build organic marketing assets. Invest in SEO, Google reviews, and genuine social content. These assets compound over time, reduce paid ad dependence, and give buyers confidence in sustainable patient acquisition.

The Bottom Line

Cosmetic dermatology is a cash-flow-rich, high-margin business model with genuinely recurring patient demand. But the spread between a well-positioned practice at 7-8x SDE and a poorly positioned one at 3-4x represents hundreds of thousands — or millions — in enterprise value. The practices that command premiums have multiple producing providers, strong retention, diversified marketing, and the operational metrics to prove it. Build those foundations before going to market, and the valuation takes care of itself.